Production (Stage)
EyePoint Pharmaceuticals, Inc.
EYPT
$9.03
$0.171.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 318.19M | 370.91M | 253.79M | 280.25M | 299.35M |
| Total Receivables | 442.00K | 607.00K | 378.00K | 1.38M | 3.02M |
| Inventory | 2.13M | 2.31M | 2.81M | 3.67M | 4.26M |
| Prepaid Expenses | 4.82M | 8.08M | 10.27M | 8.57M | 9.61M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 1.40M | 1.41M | 1.30M | 1.07M | 1.48M |
| Total Current Assets | 326.98M | 383.31M | 268.55M | 294.93M | 317.71M |
|
|
|||||
| Total Current Assets | 326.98M | 383.31M | 268.55M | 294.93M | 317.71M |
| Net Property, Plant & Equipment | 29.55M | 29.18M | 29.80M | 29.17M | 11.39M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 6.03M | 5.98M | 2.57M | 150.00K | 150.00K |
| Total Assets | 362.56M | 418.47M | 300.92M | 324.25M | 329.25M |
|
|
|||||
| Total Accounts Payable | 16.42M | 11.72M | 7.34M | 14.30M | 7.08M |
| Total Accrued Expenses | 18.10M | 17.96M | 13.89M | 12.70M | 15.28M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 1.77M | 1.25M | 1.19M | 1.13M | 1.10M |
| Total Finance Division Other Current Liabilities | 5.39M | 18.12M | 26.38M | 33.98M | 39.12M |
| Total Other Current Liabilities | 5.39M | 18.12M | 26.38M | 33.98M | 39.12M |
| Total Current Liabilities | 41.68M | 49.05M | 48.79M | 62.10M | 62.58M |
|
|
|||||
| Total Current Liabilities | 41.68M | 49.05M | 48.79M | 62.10M | 62.58M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 22.31M | 21.86M | 21.92M | 22.16M | 4.62M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 177.00K | 11.06M | 11.47M | 11.68M | 12.11M |
| Total Liabilities | 64.17M | 81.96M | 82.18M | 95.94M | 79.31M |
|
|
|||||
| Common Stock & APIC | 1.22B | 1.21B | 1.05B | 1.03B | 1.02B |
| Retained Earnings | -918.21M | -873.02M | -831.62M | -802.26M | -771.43M |
| Treasury Stock & Other | 923.00K | 1.03M | 1.17M | 792.00K | 836.00K |
| Total Common Equity | 298.40M | 336.50M | 218.73M | 228.31M | 249.93M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 298.40M | 336.50M | 218.73M | 228.31M | 249.93M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 298.40M | 336.50M | 218.73M | 228.31M | 249.93M |
|
|
|||||